Intellectual property, drug licensing, freedom of information, and public health

Lancet

Volumn 352, Issue 9129, 1998, Pages 726-729

  Roberts, Ian ^a   Po, Alain Li Wan ^b   Chalmers, Lain ^c  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^c UK COCHRANE CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG INFORMATION; LICENSING; PATENT; PRIORITY JOURNAL; PUBLIC HEALTH; SHORT SURVEY;

EID: 0344541925     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(98)07600-4     Document Type: Article

References (19)

1. Ollila E, Hemmin ki E. Secrecy of drug regulation. Int J Risk Safety Med 1996; 9: 161-72.
2. Dent T, Hawke S. Too soon to market. BMJ 1997; 315: 1248-49.
3. Boseley S. Hard to swallow. Guardian 1998; 23 April: 2.
4. Montagne M. The role of clinical research in the drug development process. In: Bleidt B, Montagne M, eds. Clinical research in pharmaceutical development. New York: Marcel Dekker, 1996: 62-77.
5. Hemminki E. Study information submitted by drug companies to licensing authorities. BMJ 1980; 280: 833-36.
6. Peters T. All about albumin: biochemistry, genetics and medical applications. San Diego, California: Academic Press, 1996.
7. Association of the British Pharmaceutical Industry. ABPI compendium of data sheets and summaries of product characteristics 1998-99. London: Association of the British Pharmaceutical Industries, 1998.
8. Mitchell P. Review sparks controversy over human albumin therapy. Lancet 1998; 352: 377.
9. Cochrane Injuries Group Albumin Reviewers. Albumin administration in critically ill patients (Cochrane Review). In: The Cochrane Library, issue 3. Oxford: Update Software, 1998.
10. Bio Products Laboratory. Albumin clinical papers. Elstree, Herts, UK: undated.
11. Brown RO, Bradley JE, Bekemeyer WB, Luther RW. Effect of albumin supplementation during parenteral nutrition on hospital morbidity. Crit CareMed 1988; 16: 1177-82.
12. Your Right to Know: the Government's proposals for a Freedom of Information Act, Cm 3818. London: Stationery Office, December 1997.
13. O'Neill RT, Anello C. Does research synthesis have a place in drug regulatory policy? Clin Res Reg Affairs 1996; 13: 23-29.
14. Human albumin therapy in critically ill patients. Public Health Link/CMO urgent communication CEM/CMO/98/11, July 24, 1998.
15. Horrobin DF. Ethical imperative to publish extends to academics too. BMJ 1995;311: 688.
16. Glaxo Wellcome. Glaxo Wellcome takes the lead on disclosure policy. News release: 12 November, 1997.
17. Office of Science and Technology. The use of scientific advice in policy making. London: Department of Trade and Industry, March 1997.
18. Insulin Dependent Diabetes Trust. The patients' manifesto. At: http ://www.traders.co.uk./in su lintrust/response.html. Accessed on 30 July 1998.
19. Blunt J, Savulescu J, Watson AJM. Meeting the challenges facing research ethics committees: some practical suggestions. BMJ 1998; 316: 58-61.